Three companies—McKesson, Cencora, and Cardinal Health—account for over 90% of the wholesale drug distribution market in the United States. Since 2019, U.S. spending on oncology drugs has risen from approximately $65 billion to $99 billion in 2023, representing nearly 45% of global oncology drug spending. In 2023, U.S. pharmaceutical expenditures reached $722.5 billion, with oncology drugs accounting for approximately 14% of total drug spending. By 2028, U.S. annual oncology spending is projected to reach $180 billion. As such, it is not surprising that these companies have sought to expand their presence within the oncology sector with the strategic acquisition and consolidation of large, oncology-focused provider networks. In the past few years, three major acquisitions have reshaped the oncology care sector.
Read the full article: Strategic Consolidation in Oncology //
Source: https://vmghealth.com/insights/blog/strategic-consolidation-in-oncology/